Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096111 | 0.92 | ADORA1 (0.43) | ADORA1KDM4EGAALMNATSHR | |
| SCHEMBL14288899 | 0.92 | ADORA1 (0.43) | ADORA1KDM4EGAALMNATSHR | |
| SCHEMBL5087436 | 0.92 | ADORA1 (0.55) | ADORA1ADORA3 | |
| SCHEMBL5090413 | 0.91 | ADORA1 (0.53) | ADORA1KDM4EGAAADORA3MARS1 | |
| SCHEMBL5096145 | 0.91 | ADORA1 (0.55) | ADORA1ADORA3 | |
| SCHEMBL5091046 | 0.87 | ADORA1 (0.47) | ADORA1KDM4EGAALMNATSHR | |
| SCHEMBL5090428 | 0.86 | ADORA1 (0.52) | ADORA1ADORA3 | |
| SCHEMBL5090462 | 0.86 | ADORA1 (0.50) | ADORA1KDM4EGAAADORA3MARS1 | |
| SCHEMBL14288901 | 0.85 | ADORA1 (0.42) | ADORA1KDM4EGAALMNATSHR | |
| SCHEMBL5087438 | 0.85 | ADORA1 (0.46) | ADORA1KDM4ELMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | GPR119, IAPP, GLP1R | ADORA1 680/4885KDM4E 2741/4885GAA 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.